EMTAGE, ABIGAIL L., MISTRY, SHAILESH N., FISCHER, PETER M., KELLAM, BARRIE and LAUGHTON, CHARLES A., 2017. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors. Journal of Biomolecular Structure & Dynamics. 35(12), 2604-2619 BAKER JG, GARDINER SM, WOOLARD J, FROMONT C, JADHAV GP, MISTRY SN, THOMPSON KS, KELLAM B, HILL SJ and FISCHER PM, 2017. Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB Journal. 31(7), 3150-3166 LEE, JONG BONG, ADROWER, CECILIA, QIN, CHAOLONG, FISCHER, PETER M., DE MOOR, CORNELIA H. and GERSHKOVICH, PAVEL, 2017. Development of Cordycepin Formulations for Preclinical and Clinical Studies: AAPS PharmSciTech AAPS PharmSciTech. (In Press.)
CRESPILLO-CASADO, ANA, CHAMBERS, JOSEPH E., FISCHER, PETER M., MARCINIAK, STEFAN J. and RON, DAVID, 2017. PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz: eLife eLife. 6, e26109 LEE, J. B., ZGAIR, A., TAHA, D. A., ZANG, X., KAGAN, L., KIM, T. H., KIM, M. G., YUN, H. Y., FISCHER, P. M. and GERSHKOVICH, P., 2017. Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays European Journal of Pharmaceutics and Biopharmaceutics. 114, 38-42 NURZYŃSKA, KATARZYNA, AUSTIN, RUPERT P., FISCHER, PETER M., BOOTH, JONATHAN and GOMMER, FRANK, 2016. Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs: Journal of Pharmaceutical Sciences Journal of Pharmaceutical Sciences. 105(6), 1858-1866 SOUKARIEH, FADI, NOWICKI, MATTHEW W., BASTIDE, AMANDINE, POYRY, TUIJA, JONES, CAROLYN, DUDEK, KATE, PATWARDHAN, GEETANJALI, MEULLENET, FRANCOIS, OLDHAM, NEIL J., WALKINSHAW, MALCOLM D., WILLIS, ANNE E. and FISCHER, PETER M., 2016. Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation. European Journal of Medicinal Chemistry. 124, 200-217 ZGAIR, ATHEER, WONG, JONATHAN CM, LEE, JONG BONG, MISTRY, JATIN, SIVAK, OLENA, WASAN, KISHOR M, HENNIG, IVO M, BARRETT, DAVID A, CONSTANTINESCU, CRIS S, FISCHER, PETER M and GERSHKOVICH, PAVEL, 2016. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research. 8(8), 3448-59
FRIDGEIRSDOTTIR GA, HARRIS R, FISCHER PM and ROBERTS CJ, 2016. Support Tools in Formulation Development for Poorly Soluble Drugs. Journal of Pharmaceutical Sciences. 105(8), 2260-9 LEE JB, ZGAIR A, KIM TH, KIM MG, YOO SD, FISCHER PM and GERSHKOVICH P, 2016. Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1040, 73-80 PATHAK M, WILMANN P, AWFORD J, LI C, HAMAD BK, FISCHER PM, DREVENY I, DEKKER LV and EMSLEY J, 2015. Coagulation factor XII protease domain crystal structure. Journal of Thrombosis and Haemostasis. 13(4), 580-591 HALLIDAY, M., RADFORD, H., SEKINE, Y., MORENO, J., VERITY, N., LE QUESNE, J., ORTORI, C. A., BARRETT, D. A., FROMONT, C., FISCHER, P. M., HARDING, H. P., RON, D. and MALLUCCI, G. R., 2015. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity Cell Death & Disease. 6, e1672 JADHAV, GOPAL P., KAUR, ISHWINDER, MARYATI, MARYATI, AIRHIHEN, BLESSING, FISCHER, PETER M. and WINKLER, G. SEBASTIAAN, 2015. Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1: Bioorganic & Medicinal Chemistry Letters Bioorganic & Medicinal Chemistry Letters. 25(19), 4219-4224 ZGAIR, ATHEER, WONG, JONATHAN C. M., SABRI, AKMAL, FISCHER, PETER M., BARRETT, DAVID A., CONSTANTINESCU, CRIS S. and GERSHKOVICH, PAVEL, 2015. Development of a simple and sensitive HPLC–UV method for the simultaneous determination of cannabidiol and Δ9-tetrahydrocannabinol in rat plasma: Journal of Pharmaceutical and Biomedical Analysis J. Pharm. Biomed. Anal.. 114(0), 145-151 SEKINE, Y., ZYRYANOVA, A., CRESPILLO-CASADO, A., FISCHER, P. M., HARDING, H. P. and RON, D., 2015. Mutations in a translation initiation factor identify the target of a memory-enhancing compound: Science Science. 348(6238), 1027-1030 NURZYŃSKA, KATARZYNA, BOOTH, JONATHAN, ROBERTS, CLIVE J., MCCABE, JAMES, DRYDEN, IAN and FISCHER, PETER M., 2015. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters: Molecular Pharmaceutics Molecular Pharmaceutics. 12(9), 3389-3398 CHEN, C.-H., GENAPATHY, S., FISCHER, P.M. and CHAN, W.C., 2014. A facile approach to tryptophan derivatives for the total synthesis of argyrin analogues Organic and Biomolecular Chemistry. 12(48), 9764-9768 LAM, F., ABBAS, A. Y., SHAO, H., TEO, T., ADAMS, J., LI, P., BRADSHAW, T. D., FISCHER, P. M., WALSBY, E., PEPPER, C., CHEN, Y., DING, J. and WANG, S., 2014. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73: Oncotarget Oncotarget. 5(17), 7691-704
REDDY, T. R., LI, C., GUO, X., FISCHER, P. M. and DEKKER, L. V., 2014. Design, synthesis and SAR exploration of tri-substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction: Bioorg Med Chem Bioorg Med Chem. 22(19), 5378-91 MARYATI, M., KAUR, I., JADHAV, G. P., OLOTU-UMOREN, L., OVEH, B., HASHMI, L., FISCHER, P. M. and WINKLER, G. S., 2014. A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity: Nucleic Acids Res Nucleic Acids Res. 42(5), e30 WALSBY, ELISABETH, PRATT, GUY, SHAO, HAO, ABBAS, ABDULLAH Y., FISCHER, PETER M., BRADSHAW, TRACEY D., BRENNAN, PAUL, FEGAN, CHRIS, WANG, SHUDONG and PEPPER, CHRIS, 2014. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine: Oncotarget Oncotarget. 5, 375-385 SHAO, HAO, SHI, SHENHUA, HUANG, SHILIANG, HOLE, ALISON, ABBAS, ABDULLAHI Y., BAUMLI, SONJA, LIU, XIANGRUI, LAM, FRANKIE, FOLEY, DAVID W., FISCHER, PETER M., NOBLE, MARTIN, ENDICOTT, JANE A., PEPPER, CHRIS and WANG, SHUDONG, 2013. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, x-ray crystal structure, SAR and anti-cancer activities: Journal of Medicinal Chemistry Journal of Medicinal Chemistry. 56, 640-659 MISTRY, S.N., BAKER, J.G., FISCHER, P.M., HILL, S.J., GARDINER, S.M. and KELLAM, B., 2013. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists Journal of Medicinal Chemistry. 56(10), 3852-3865 MORENO, J.A., HALLIDAY, M., MOLLOY, C., RADFORD, H., VERITY, N., AXTEN, J.M., ORTORI, C.A., WILLIS, A.E., FISCHER, P.M., BARRETT, D.A. and MALLUCCI, G.R., 2013. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice: Science Translational Medicine Science Translational Medicine. 5(206), 206ra138 MARYATI M, KAUR I, JADHAV GP, OLOTU-UMOREN L, OVEH B, HASHMI L, FISCHER PM and WINKLER GS, 2013. A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity. Nucleic acids research. (In Press.)
SHAO H, SHI S, FOLEY DW, LAM F, ABBAS AY, LIU X, HUANG S, JIANG X, BAHARIN N, FISCHER PM and WANG S, 2013. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. European journal of medicinal chemistry. 70, 447-55 DICKENS MP, ROXBURGH P, HOCK A, MEZNA M, KELLAM B, VOUSDEN KH and FISCHER PM, 2013. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic & medicinal chemistry. 21(22), 6868-77 LIU, XIANGRUI, LAM, FRANKIE, SHI, SHENHUA, FISCHER, PETER M and WANG, SHUDONG, 2012. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Investigational new drugs. 30(3), 889-897 SULTANA, R., MCNEILL, D.R., ABBOTTS, R., MOHAMMED, M.Z., ZDZIENICKA, M.Z., QUTOB, H., SEEDHOUSE, C., LAUGHTON, C.A., FISCHER, P.M., PATEL, P.M., WILSON, D.M. and MADHUSUDAN, S., 2012. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors International Journal of Cancer. 131(10), 2433-2444 ROXBURGH P, HOCK AK, DICKENS MP, MEZNA M, FISCHER PM and VOUSDEN KH, 2012. Small Molecules That Bind The Mdm2 Ring Stabilize And Activate P53. Carcinogenesis. (In Press.)
REDDY, T.R.K., LI, C., FISCHER, P.M. and DEKKER, L.V., 2012. Three-dimensional pharmacophore design and biochemical screening identifies substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction ChemMedChem. 7(8), 1435-1446 HOLE, ALISON, BAUMLI, SONJA, SHAO, HAO, SHI, SHENHUA, PEPPER, CHRIS, FISCHER, PETER M., WANG, SHUDONG, ENDICOTT, JANE ANNE and NOBLE, MARTIN, 2012. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity: J. Med. Chem. Journal of Medicinal Chemistry. Ahead of Print BYRNE, C., MCEWAN, P.A., EMSLEY, J., FISCHER, P.M. and CHAN, W.C., 2011. End-stapled homo and hetero collagen triple helices: a click chemistry approach Chemical Communications. 47(9), 2589-2591 WANG, S., MEADES, C., WOOD G., O'BOYLE, J., MCINNES, C. and FISCHER, P.M., 2011. Pyrimidine compounds US07897605 03/01/2011 00:00:00
LIU, XIANGRUI, SHI, SHENHUA, LAM, FRANKIE, PEPPER, CHRIS, FISCHER, PETER M and WANG, SHUDONG, 2011. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International journal of cancer. Journal international du cancer. MOHAMMED, M.Z., VYJAYANTI, V.N., LAUGHTON, C.A., DEKKER, L.V., FISCHER, P.M., WILSON, D.M., ABBOTTS, R., SHAH, S., PATEL, P.M., HICKSON, I.D. and MADHUSUDAN, S., 2011. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines British Journal of Cancer. 104(4), 653-663 REDDY, T.R.K., LI, C., GUO, X., MYRVANG, H.K., FISCHER, P.M. and DEKKER, L.V., 2011. Design, synthesis, and SAR exploration of 1-substituted 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one analogues as inhibitors of the annexin A2–S100A10 protein interaction Journal of Medicinal Chemistry. 54(7), 2080-2094 WILSON SC, ATRASH B, BARLOW C, ECCLES S, FISCHER PM, HAYES A, KELLAND L, JACKSON W, JARMAN M, MIRZA A, MORENO J, NUTLEY BP, RAYNAUD FI, SHELDRAKE P, WALTON M, WESTWOOD R, WHITTAKER S, WORKMAN P and MCDONALD E, 2011. Design, Synthesis And Biological Evaluation Of 6-Pyridylmethylaminopurines As Cdk Inhibitors. Bioorganic & Medicinal Chemistry. 19(22), 6949-65 JADHAV GP, CHHABRA SR, TELFORD G, HOOI DS, RIGHETTI K, WILLIAMS P, KELLAM B, PRITCHARD DI and FISCHER PM, 2011. Immunosuppressive but non-LasR-inducing analogues of the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-l-homoserine lactone. Journal of Medicinal Chemistry. 54(9), 3348-3359 WANG, S., MIDGLEY, C.A., SCAËROU, F., GRABAREK, J.B., GRIFFITHS, G., JACKSON, W., KONTOPIDIS, G., MCCLUE, S.J., MCINNES, C., MEADES, C., MEZNA, M., PLATER, A., STUART, I., THOMAS, M.P., WOOD, G., CLARKE, R.G., BLAKE, D.G., ZHELEVA, D.I., LANE, D.P., JACKSON, R.C., GLOVER, D.M. and FISCHER, P.M., 2010. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors Journal of Medicinal Chemistry. 53(11), 4367-4378 WANG, S., GRIFFITHS, G., MIDGLEY, C.A., BARNETT, A.L., COOPER, M., GRABAREK, J., INGRAM, L., JACKSON, W., KONTOPIDIS, G., MCCLUE, S.J., MCINNES, C., MCLACHLAN, J., MEADES, C., MEZNA, M., STUART, I., THOMAS, M.P., ZHELEVA, D.I., LANE, D.P., JACKSON, R.C., GLOVER, D.M., BLAKE, D.G. and FISCHER, P.M., 2010. Discovery and characterization of 2-anilino-4- (thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents Chemistry & Biology. 17(10), 1111-1121 MCINTYRE, N.A., MCINNES, C., GRIFFITHS, G., BARNETT, A.L., KONTOPIDIS, G., SLAWIN, A.M.Z., JACKSON, W., THOMAS, M., ZHELEVA, D.I., WANG, S., BLAKE, D.G., WESTWOOD, N.J. and FISCHER, P.M., 2010. Design, synthesis and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors Journal of Medicinal Chemistry. 53(5), 2136-2145 LI, C., REDDY, T.R.K., FISCHER, P.M. and DEKKER, L.V., 2010. A Cy5-labelled S100A10 tracer used to identify inhibitors of the protein interaction with Annexin A2 ASSAY and Drug Development Technologies. 8(1), 85-95 DICKENS, M.P., FITZGERALD, R. and FISCHER, P.M., 2009. Small-molecule inhibitors of MDM2 as new anticancer therapeutics Seminars in Cancer Biology. 20(1), 10-18 KONTOPIDIS, G., ANDREWS, M.J, MCINNES, C., PLATER, A., INNES, L., RENACHOWSKI, S., COWAN, A. and FISCHER, P.M., 2009. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem. 4(7), 1120-8 FISCHER, P.M., 2009. Cap in hand: targeting eIF4E Cell Cycle. 8(16), 2535-2541 MAZANETZ, M.P., WITHERS, I.M., LAUGHTON, C.A. and FISCHER, P.M., 2009. A Study of CDK2 Inhibitors Using a Novel 3D-QSAR Method Based on Exploitation of Receptor Flexibility QSAR & Combinatorial Science. 28(8), 878-884 BAKER, J.G., PROUDMAN, R.G.W., HAWLEY, N.C., FISCHER, P.M. and HILL, S.J., 2008. Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human β1-adrenoceptor Molecular Pharmacology. 74(5), 1246-1260 HUBER, K., PATEL, P., ZHANG, L., EVANS, H., WESTWELL, A.D., FISCHER, P.M., CHAN, S. and MARTIN, S., 2008. 2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation Molecular Cancer Therapeutics. 7(1), 143-151 WITHERS, I.M., MAZANETZ, M.P., WANG, H., FISCHER, P.M. and LAUGHTON, C.A., 2008. Active site pressurization: a new tool for structure-guided drug design and other studies of protein flexibility Journal of Chemical Information and Modeling. 48(7), 1448-1454 MAZANETZ, M.P., WITHERS, I.M., LAUGHTON, C.A. and FISCHER, P.M., 2008. Exploiting glycogen synthase kinase 3beta flexibility in molecular recognition. Biochemical Society Transactions. 36(1), 55-58
PATWARDHAN, G, OLDHAM, N.J. and FISCHER, P.M., 2008. Structure-guided design of inhibitors of the eukaryotic initiation factor 4E (eIF4E) mRNA-cap interaction as anti-cancer agents In: European Journal of Cancer Supplements, Volume 6, Issue 9. 106 (In Press.)
FISCHER, P.M., 2008. Computational chemistry approaches to drug discovery in signal transduction Biotechnology Journal. 3(4), 452-470
FISCHER, P.M., 2008. Turning down tau phosphorylation Nature Chemical Biology. 4(8), 448-449 FISCHER, P.M., 2008. Cell cycle inhibitors in cancer: current status and future directions. In: NEIDLE, S., ed., Cancer Drug Design and Discovery Academic Press. 253-283
FISCHER, PM., 2007. Medicinal Research Reviews. 27(6), 755-795
BROWN, C.J., MCNAE, I., FISCHER, P.M. and WALKINSHAW, M.D., 2007. Crystallographic and Mass Spectrometric Characterisation of eIF4E with N(7)-alkylated Cap Derivatives Journal of Molecular Biology. 372(1), 7-15 MAZANETZ, M.P. and FISCHER, P.M., 2007. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Reviews Drug Discovery. 6(6), 464-479 FISCHER, P., COMIS, A., TYLER, M. and HOWDEN, M., 2007. Oral and parenteral immunization with synthetic retro-inverso peptides induce antibodies that cross-react with native peptides and parent antigens. Indian Journal of Biochemistry & Biophysics. 44(3), 140-144
SPICHAL, L., KRYSTOF, V., PAPRSKAROVA, M., LENOBEL, R., STYSKALA, J., BINAROVA, P., CENKLOVA, V., DE VEYLDER, L., INZE, D., KONTOPIDIS, G., FISCHER, P.M, SCHMULLING, T. and STRNAD, M., 2007. Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases Journal of Biological Chemistry. 282(19), 14356-14363 FISCHER, P.M., 2007. Analytical techniques: Smarter ways to screen for drug leads. Current Opinion in Chemical Biology. 11(5), 477-479 KONTOPIDIS, G., MCINNES, C., PANDALANENI, S.R., MCNAE, I., GIBSON, D., MEZNA, M., THOMAS, M., WOOD, G., WANG, S., WALKINSHAW, M.D. and FISCHER, P.M., 2006. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design Chemistry & Biology. 13(2), 201-211 MCINNES, C., MAZUMDAR, A., MEZNA, M., MEADES, C., MIDGLEY, C., SCAEROU, F., CARPENTER, L., MACKENZIE, M., TAYLOR, P., WALKINSHAW, M., FISCHER, P.M. and GLOVER, D., 2006. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance Nature Chemical Biology. 2(11), 608-617 WANG, S., ZHELEV, N.Z., DUFF, S. and FISCHER, P.M., 2006. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin Bioorganic & Medicinal Chemistry Letters. 16(10), 2628-2631 KRYSTOF, V., CANKAR, P., FRYSOVA, I., SLOUKA, J., KONTOPIDIS, G., DZUBAK, P., HAJDUCH, M., SROVNAL, J., DE AZEVEDO, W.F. JR, ORSAG, M., PAPRSKAROVA, M., ROLCIK, J., LATR, A., FISCHER, P.M. and STRNAD, M., 2006. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects Journal of Medicinal Chemistry. 49(22), 6500-6509 ANDREWS, M.J.I., KONTOPIDIS, G., MCINNES, C., PLATER, A., INNES, L., COWAN, A., JEWSBURY, P. and FISCHER, P.M., 2006. REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors ChemBioChem. 7(12), 1909-1915 THOMAS, M.P., MCINNES, C. and FISCHER, P.M., 2006. Protein structures in virtual screening: a case study with CDK2. Journal of Medicinal Chemistry. 49(1), 92-104 KONTOPIDIS, G., WU, S.-Y., ZHELEVA, D.I., TAYLOR, P., MCINNES, C., LANE, D.P., FISCHER, P.M. and WALKINSHAW, M.D., 2005. Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design Proceedings of the National Academy of Sciences of the United States of America. 102(6), 1871-1876 FISCHER, P.M. and GIANELLA-BORRADORI, A., 2005. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opinion on Investigational Drugs. 14(4), 457-477 FISCHER, P.M., 2005. Protein-protein interactions in drug discovery Drug Design Reviews Online. 2(3), 179-207 KRYSTOF, V., MCNAE, I.W., WALKINSHAW, M.D., FISCHER, P.M., MÜLLER, P., VOJTESEK, B., ORSÁG, M., HAVLÍCEK, L. and STRNAD, M., 2005. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cellular and Molecular Life Sciences. 62(15), 1763-1771 MCINNES, C., MEZNA, M. and FISCHER, P.M., 2005. Progress in the discovery of polo-like kinase inhibitors. Current Topics in Medicinal Chemistry. 5(2), 181-197 RAYNAUD, F.I., WHITTAKER, S.R., FISCHER, P.M., MCCLUE, S., WALTON, M.I., BARRIE, S.E., GARRETT, M.D., ROGERS, P., CLARKE, S.J., KELLAND, L.R., VALENTI, M., BRUNTON, L., ECCLES, S., LANE, D.P. and WORKMAN, P., 2005. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clinical Cancer Research. 11(13), 4875-4887 MCINNES, C. and FISCHER, P.M., 2005. Strategies for the design of potent and selective kinase inhibitors. Current Pharmaceutical Design. 11(14), 1845-1863 NUTLEY, B.P., RAYNAUD, F.I., WILSON, S.C., FISCHER, P.M., HAYES, A., GODDARD, P.M., MCCLUE, S.J., JARMAN, M., LANE, D.P. and WORKMAN, P., 2005. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Molecular Cancer Therapeutics. 4(1), 125-139
UHRINOVA, S., UHRIN, D., POWERS, H., WATT, K., ZHELEVA, D., FISCHER, P.M., MCINNES, C. and BARLOW, P.N., 2005. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. Journal of Molecular Biology. 350(3), 587-598 WANG, S., MEADES, C., WOOD, G., OSNOWSKI, A., ANDERSON, S., YUILL, R., THOMAS, M., MEZNA, M., JACKSON, W., MIDGLEY, C., GRIFFITHS, G., FLEMING, I., GREEN, S., MCNAE, I., WU, S.Y., MCINNES, C., ZHELEVA, D., WALKINSHAW, M.D. and FISCHER, P.M., 2004. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity Journal of Medicinal Chemistry. 47(7), 1662-1675 MCINNES, C., WANG, S., ANDERSON, S., O'BOYLE, J., JACKSON, W., KONTOPIDIS, G., MEADES, C., MEZNA, M., THOMAS, M., WOOD, G., LANE, D.P. and FISCHER, P.M., 2004. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors Chemistry & Biology. 11(4), 525-534 WANG, S., WOOD, G., MEADES, C., GRIFFITHS, G., MIDGLEY, C., MCNAE, I., MCINNES, C., ANDERSON, S., JACKSON, W., MEZNA, M., YUILL, R., WALKINSHAW, M. and FISCHER, P.M., 2004. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors Bioorganic and Medicinal Chemistry Letters. VOL 14(NUMBER 16), 4237-4240 FISCHER, P.M., 2004. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry. 11(12), 1563-1583
FISCHER, P.M., 2004. The Use of CDK Inhibitors in Oncology: A Pharmaceutical Perspective Cell Cycle. VOL 3(ISSU 6), 742-746
FISCHER, P.M., GLOVER, D.M. and LANE, D.P., 2004. Targeting the cell cycle Drug Discovery Today. VOL 1(NUMBER 4), 417-423 RAYNAUD, F.I., FISCHER, P.M., NUTLEY, B.P., GODDARD, P.M., LANE, D.P. and WORKMAN, P., 2004. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Molecular Cancer Therapeutics. 3(3), 353-362
ANDREWS, M.J.I., MCINNES, C., KONTOPIDIS, G., INNES, L., COWAN, A., PLATER, A. and FISCHER, P.M., 2004. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Organic and Biomolecular Chemistry. 2(19), 2735-2741 FISCHER, P.M., 2004. Apoptosis and Chemotherapy: Helping Cancer Cells to Die European BioPharmaceutical Review. Summer, 78-84
LANE, D.P. and FISCHER, P.M., 2004. Drug development: Turning the key on p53 Nature. ISSU 6977, 789-790
WU, S.Y., MCNAE, I., KONTOPIDIS, G., MCCLUE, S.J., MCINNES, C., STEWART, K.J., WANG, S., ZHELEVA, D.I., MARRIAGE, H., LANE, D.P., TAYLOR, P., FISCHER, P.M. and WALKINSHAW, M.D., 2003. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop Structure. 11(4), 399-410 KONTOPIDIS, G., ANDREWS, M.J.I., MCINNES, C., COWAN, A., POWERS, H., INNES, L., PLATER, A., GRIFFITHS, G., PATERSON, D., ZHELEVA, D.I., LANE, D.P., GREEN, S., WALKINSHAW, M.D. and FISCHER, P.M., 2003. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 11(12), 1537-1546 SAREK, J., KLINOT, J., DZUBAK, P., KLINOTOVA, E., NOSKOVA, V., KRECEK, V., KORINKOVA, G., THOMSON, J.O., JANOST'AKOVA, A., WANG, S., PARSONS, S., FISCHER, P.M., ZHELEV, N.Z. and HAJDUCH, M., 2003. New Lupane Derived Compounds with Pro-Apoptotic Activity in Cancer Cells: Synthesis and Structure-Activity Relationships Journal of Medicinal Chemistry. VOL 46(PART 25), 5402-5415 FISCHER, P.M., 2003. Diketopiperazines in peptide and combinatorial chemistry. Journal of Peptide Science. 9(1), 9-35 FISCHER, P.M., ENDICOTT, J. and MEIJER, L., 2003. Cyclin-dependent kinase inhibitors. Progress in Cell Cycle Research. 5, 235-248
MCINNES, C., ANDREWS, M.J.I., ZHELEVA, D.I., LANE, D.P. and FISCHER, P.M., 2003. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current Medicinal Chemistry - Anti-Cancer Agents. 3(1), 57-69 FISCHER, P.M. and GIANELLA-BORRADORI, A., 2003. CDK inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs. 12(6), 955-970 FISCHER, P.M., BELL, G., MIDGLEY, C., SLEIGH, R. and GLOVER, D.M., 2003. Cell cycle target validation: approaches and successes Targets. 2(4), 154-161 FISCHER, P.M., 2003. CNIO cancer conference: targeted search for anticancer drugs. Expert Opinion on Investigational Drugs. 12(6), 1039-1044 FISCHER, P.M., 2003. CDK versus GSK-3 inhibition: a purple haze no longer? Chemistry & Biology. 10(12), 1144-1146 ZHELEVA, D.I., LANE, D.P. and FISCHER, P.M., 2003. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. Mini Reviews in Medicinal Chemistry. 3(3), 257-270 ATKINSON, G.E., COWAN, A., MCINNES, C., ZHELEVA, D.I., FISCHER, P.M. and CHAN, W.C., 2002. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorganic and Medicinal Chemistry Letters. 12(18), 2501-2505 MCCLUE, S.J., BLAKE, D., CLARKE, R., COWAN, A., CUMMINGS, L., FISCHER, P.M., MACKENZIE, M., MELVILLE, J., STEWART, K., WANG, S., ZHELEV, N., ZHELEVA, D. and LANE, D.P., 2002. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). International Journal of Cancer. 102(5), 463-468 CHAN, W.C., ATKINSON, G.E., COWAN, A., MCINNES, C. and FISCHER, P.M., 2002. p21(WAF1)-derived octapeptide inhibitors of CDK-cyclin complex: The effect of structural variants of the C-terminal Phe residue Journal of Peptide Science. 8, S146
ZHELEVA, D.I., MCINNES, C., GAVINE, A., ZHELEV, N.Z., FISCHER, P.M. and LANE, D.P., 2002. Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A Journal of Peptide Research. 60(5), 257-270 ORNING, L., FISCHER, P.M., HU, C.-K., AGNER, E., ENGEBRETSEN, M., HUSBYN, M., PETERSEN, L.B., ORVIM, U., LLINAS, M. and SAKARIASSEN, K.S., 2002. A Cyclic Pentapeptide Derived from the Second EGF-Like Domain of Factor VII Is an Inhibitor of Tissue Factor Dependent Coagulation and Thrombus Formation Thrombosis and Haemostasis. VOL 87(PART 1), 13-21
WANG, S., MCCLUE, S.J., FERGUSON, J.R., HULL, J.D., STOKES, S., PARSONS, S., WESTWOOD, R. and FISCHER, P.M., 2001. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer Tetrahedron Asymmetry. VOL 12(NUMBER 20), 2891-2894 FISCHER, P.M., 2001. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Current Opinion in Drug Discovery & Development. 4(5), 623-634
HU, C.K, . LLINÁS, M., AGNER, K.E., ORNING, L., SAKARIASSEN, K.S. and FISCHER, P.M., 2001. Synthesis, biological activity, and solution structures of a cyclic dodecapeptide from the EGF-2 domain of blood coagulation factor VII. Journal of Peptide Research. 57(6), 462-72 FISCHER, P.M., ZHELEV, N.Z., WANG, S., MELVILLE, J.E., FÅHRAEUS, R. and LANE, D.P., 2000. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. Journal of Peptide Research. 55(2), 163-172 ZHELEVA, D.I., ZHELEV, N.Z., FISCHER, P.M., DUFF, S.V., WARBRICK, E., BLAKE, D.G. and LANE, D.P., 2000. A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. Biochemistry.. 39(25), 7388-7397 FISCHER, P.M and LANE, D.P., 2000. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Current Medicinal Chemistry. 7(12), 1213-1245
FISCHER, P.M., ZHELEV, N.Z., FAHRAEUS, R., BALL, K.L, WARBRICK, E. and LANE, D.P., 1999. Intracellular delivery of cell-cycle inhibitor peptides by penetratin, a 16-residue peptide from the Antennapedia homeoprotein In: Peptides 1998. 700-701
FÅHRAEUS, R, FISCHER, P, KRAUSZ, E and LANE, D P, 1999. New approaches to cancer therapies. Journal of Pathology. 187(1), 138-146 KLEPP, K.O., CUTHBERTSON, A.S., FISCHER, P.M., SANDOSHAM, J, HARTMANN, M., HIEBL, J., KOLLMANN, H., KREMMINGER, P. and ROVENSZKY, F., 1999. The crystal structure of N,N’-bis-(1,3-dihydroxy-2-methylprop-2-yl)-pyrazine-2,3-dicarboxamide semihydrate Zeitschrift fuer Naturforschung. 54b(8), 1027-1032